1-6 of 6
Catherine B. Meador
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Catherine B. Meador, Subba R. Digumarthy, Beow Y. Yeap, Yin P. Hung, Mari Mino-Kenudson, Anna F. Farago, Rebecca S. Heist, J. Paul Marcoux, Deepa Rangachari, David A. Barbie, Zofia Piotrowska
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-2350
Published: 10 December 2024
View article titled, Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Open the PDF for Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes in another window
Includes: Supplementary data
Journal Articles

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Talal El Zarif, Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, John Canniff, Brad Fortunato, Rong Li, Mandeep K. Banwait, Karl Semaan, Marc Eid, Henry Long, Yin P. Hung, Navin R. Mahadevan, David A. Barbie, Matthew G. Oser, Zofia Piotrowska, Toni K. Choueiri, Sylvan C. Baca, Aaron N. Hata, Matthew L. Freedman, Jacob E. Berchuck
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3798–3811.
https://doi.org/10.1158/1078-0432.CCR-24-0466
Published: 03 September 2024
View article titled, Detecting Small Cell Transformation in Patients with Advanced <em>EGFR</em> Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Open the PDF for Detecting Small Cell Transformation in Patients with Advanced <em>EGFR</em> Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling in another window
Includes: Supplementary data
Journal Articles

Effective Cancer Genotyping—Many Means to One End

Catherine B. Meador, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4583–4585.
https://doi.org/10.1158/1078-0432.CCR-19-1233
Published: 01 August 2019
View article titled, Effective Cancer Genotyping—Many Means to One End
Open the PDF for Effective Cancer Genotyping—Many Means to One End in another window
Journal Articles

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 426–435.
https://doi.org/10.1158/1078-0432.CCR-15-0620
Published: 14 January 2016
View article titled, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Open the PDF for Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Catherine B. Meador, Christine M. Micheel, Mia A. Levy, Christine M. Lovly, Leora Horn, Jeremy L. Warner, Douglas B. Johnson, Zhongming Zhao, Ingrid A. Anderson, Jeffrey A. Sosman, Cindy L. Vnencak-Jones, Kimberly B. Dahlman, William Pao
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2264–2275.
https://doi.org/10.1158/1078-0432.CCR-13-1591
Published: 30 April 2014
View article titled, Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
Open the PDF for Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies in another window
Journal Articles

Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Valentina Pirazzoli, Marc Ladanyi, Lu Wang, Xi Chen, Rosana Eisenberg, Darren Cross, William Pao
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2_Supplement): B10.
https://doi.org/10.1158/1078-0432.14AACRIASLC-B10
Published: 16 January 2014
View article titled, Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.